Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2025-08-26 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
内幕信息知情人登记管理制度
Governance Information Classification · 95% confidence The document is a detailed internal policy document titled "内幕信息知情人登记管理制度" (Insider Information Insider Registration Management System) issued by 拓新药业集团股份有限公司. It outlines the rules, responsibilities, and procedures for managing insider information and insider information insiders, including registration, confidentiality, and legal compliance. It references relevant laws and regulations, but it is not a financial report, earnings release, or announcement of voting results. It is a governance-related document detailing internal rules and compliance practices related to insider information management. The document length is 7727 characters, which is substantial and contains detailed procedural content rather than a brief announcement or certification. Therefore, the most appropriate classification is Governance Information (CGR).
2025-08-26 Chinese
内部审计制度
Audit Report / Information Classification · 95% confidence The document is titled '内部审计制度' (Internal Audit System) of 拓新药业集团股份有限公司 dated August 2025. It details the internal audit policies, responsibilities, procedures, and governance related to internal audit functions within the company. It does not contain financial statements, earnings data, or shareholder meeting materials. It is a detailed internal governance and procedural document focused on audit and internal control systems. This fits best under 'Audit Report / Information (AR)' as it relates to internal audit policies and procedures rather than a full annual report or other categories. The document length (5772 characters) and content confirm it is a substantive internal audit information document, not a brief announcement or certification. Therefore, the classification is AR with high confidence. FY 2025
2025-08-26 Chinese
控股股东及实际控制人行为规范
Governance Information Classification · 95% confidence The document is titled "控股股东及实际控制人行为规范" which translates to "Code of Conduct for Controlling Shareholders and Actual Controllers" of a company. It contains detailed governance rules, obligations, and behavioral norms for controlling shareholders and actual controllers, referencing laws, regulations, and stock exchange rules. It is a governance-related document focusing on internal rules and compliance rather than financial results, audit, or capital changes. It does not present financial statements or earnings data, nor is it an announcement or a brief summary. The document is lengthy (8048 characters) and substantive, indicating it is the actual governance code rather than a mere announcement. Therefore, the most appropriate classification is Governance Information (CGR).
2025-08-26 Chinese
投资者关系管理制度
Governance Information Classification · 95% confidence The document is titled '投资者关系管理制度' which translates to 'Investor Relations Management System' and details the company's policies and procedures for managing investor relations. It includes governance principles, communication methods with investors, responsibilities of company personnel, and compliance with relevant laws and regulations. There is no financial data, earnings information, or report publication announcement. The document is a governance-related policy document outlining internal rules and practices for investor relations management. Therefore, it fits best under Governance Information (CGR). The document length (6621 characters) and content confirm it is a substantive policy document, not a brief announcement or report publication notice.
2025-08-26 Chinese
股东会议事规则
Governance Information Classification · 100% confidence The document is titled "股东会议事规则" which translates to "Rules of Procedure for Shareholders' Meetings" of 拓新药业集团股份有限公司. It details the procedures, legal basis, and operational rules for convening and conducting shareholders' meetings, including rights, voting procedures, proposal submissions, and meeting conduct. It does not contain financial data, earnings, audit results, or announcements of voting results. Instead, it is a governance document outlining internal rules and practices related to shareholder meetings. Therefore, it fits the category of Governance Information (CGR). The document length (7,560 characters) and content confirm it is a full governance rules document, not a brief announcement or notice.
2025-08-26 Chinese
2025年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2025 年半年度报告摘要" which translates to "2025 Semi-Annual Report Summary." It contains detailed financial data such as revenue, net profit, earnings per share, total assets, and shareholder information for the half-year period. The document is a summary of the half-year report, indicating it is a financial report for a period shorter than a full fiscal year. It is not merely an announcement or a certification but contains substantive financial data and analysis. Therefore, it fits the definition of an Interim / Quarterly Report (IR). The document length is 2513 characters, which is sufficient for a summary report and not just a brief announcement. Hence, the classification is IR with high confidence. H1 2025
2025-08-26 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.